Skip to main content
S&P 5007,353.73-4.36%DOW51,523.06-3.44%NASDAQ24,315.00-5.52%BTC$76,146.00-5.78%ETH$2,238.88-7.96%GOLD$4,074.90-0.94%OIL$91.08+0.62%
Smart Investors Daily
SID Premium
IC

NASDAQ · ICUCW

SeaStar Medical Holding Corporation

Healthcare · Biotechnology

$0.01

Up+$0.00 (+15.09%)

Updated Nov 6, 2026, 2:28 AM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
475.82K
P/E ratio
-0.66
Dividend yield
0.00%
52-week range
$0.01 – $0.08
Volume
14.37K
Avg. volume
69.42K

Price performance · ICUCW

ICUCW price history

1M range · 13 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

ICUCW closed at $0.01 after 13 trading sessions, down 38.73% for the selected period.

Last close
$0.01
Period change
-38.73%
Period low
$0.01
Period high
$0.02
Daily close
View OHLC price history
ICUCW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$0.013$0.013$0.0106$0.010614.37K
Nov 2, 2026$0.01$0.0137$0.01$0.0136150.5K
Oct 30, 2026$0.0125$0.0125$0.0109$0.0109140.86K
Oct 28, 2026$0.0152$0.0169$0.0121$0.0167198.1K
Oct 27, 2026$0.0153$0.0153$0.0152$0.01534.38K
Oct 26, 2026$0.0155$0.0156$0.0151$0.015520.62K
Oct 23, 2026$0.019$0.019$0.0156$0.0156440
Oct 22, 2026$0.02$0.02$0.02$0.02102
Oct 21, 2026$0.0248$0.0249$0.0201$0.02023.1K
Oct 20, 2026$0.0249$0.0249$0.02$0.02012.76K
Oct 14, 2026$0.0202$0.0202$0.02$0.0210.49K
Oct 13, 2026$0.0156$0.0183$0.0156$0.015620.03K
Oct 12, 2026$0.0176$0.0177$0.0154$0.017318.16K

Latest ICUCW news

The latest Smart Investors Daily articles mentioning ICUCW.

Stock researchCompany · Overview

ICUCW research

Overview

Company profile and research snapshot.

Company profile

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

ICU: QUELIMMUNE® Demonstrates Statistically Significant Survival Benefit in SAVE Registry Patients

By David Bautz, PhD NASDAQ: ICU READ THE FULL ICU RESEARCH REPORT Business Update Statistically Significant Survival Benefit Shown for QUELIMMUNE® On October 22, 2026, SeaStar Medical Holding Corp. (ICU) announced the presentation of new positive data at the American Society of Nephrology (ASN) Kidney Week 2026. A copy of the presentation can be found here . The analysis compared survival in

Yahoo · Oct 22, 2026

SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKI

New late-breaking data presented today at ASN Kidney Week 2026 QUELIMMUNE (SCD-PED) treatment group demonstrates statistically significant higher survival in the primary analysis at Day 60, Day 90, and at hospital discharge versus comparator cohort No device-related adverse events (AEs) occurred in patients treated with QUELIMMUNE DENVER, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatmen

Yahoo · Oct 14, 2026

SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology Award

Award recognizes Dr. Chung’s extraordinary career as an internationally known expert in burn critical care, combat casualty care, acute organ failure, and extracorporeal organ support Keynote presentation and award ceremony to occur at Update in Critical Care Nephrology 2026 DENVER, Oct. 14, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and p

Yahoo · Oct 7, 2026

FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

Potentially accelerates development, assessment, and review for approval by FDA Sepsis impacts about 1.7 million U.S. adults annually and contributes to nearly one in three in-hospital deaths DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that the U.S. Food and Drug Administration (F

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By